Life-saving effect of convalescent plasma treatment in covid-19 disease: Clinical trial from eastern Anatolia

Basit Öğe Kaydı
dc.authoridErkurt, Mehmet Ali/0000-0002-3285-417X
dc.authoridKAYA, Emin/0000-0001-8605-8497
dc.authoridSARICI, Ahmet/0000-0002-5916-0119
dc.authoridBERBER, Ilhami/0000-0003-3312-8476
dc.authorwosidErkurt, Mehmet Ali/ABI-7232-2020
dc.authorwosidKAYA, Emin/W-2951-2017
dc.authorwosidSARICI, Ahmet/ABI-7512-2020
dc.authorwosidBERBER, Ilhami/ABI-6231-2020
dc.contributor.authorErkurt, Mehmet Ali
dc.contributor.authorSarici, Ahmet
dc.contributor.authorBerber, Ilhami
dc.contributor.authorKuku, Irfan
dc.contributor.authorKaya, Emin
dc.contributor.authorOzgul, Mustafa
dc.date.accessioned2024-08-04T20:47:27Z
dc.date.available2024-08-04T20:47:27Z
dc.date.issued2020
dc.departmentİnönü Üniversitesien_US
dc.description.abstractAim: Convalescent Plasma (CP) therapy is of interest as no vaccine or specific treatment is available for emerging viruses such as severe acute respiratory syndrome coronavirus 2 causing Covid-19. It was aimed to report the results of our patients who underwent CP in the treatment of Covid-19. Methods: CP treatment was applied to 26 Covid-19 patients in intensive care unit who had quantitative reverse transcriptase-polymerase chain reaction positive Sars-Cov-2 infection. Plasma was collected at least 14 days after complete recovery from patients who had mild or moderate infection with Sars-Cov-2 infection. The collected CP (200cc) were applied to severe Covid-19 patients. Laboratory values of patients just before CP and after 7 days were compared. Results: There were no statistically significant differences in leukocyte, neutrophil, lymphocyte, platelet, CRP, ferritin, LDH, ALT, AST, sO(2) and total bilirubin values just before and after 1 week of CP. A statistically significant difference was found between age and lymphocyte values of living and dying patients. The patients who died were determined to have older age (74,6 vs 61,85, p-0,018) and more severe lymphopenia (0,47 vs 1,18, p = 0,001). Conclusion: CP therapy has the potential to provide immediate and promising treatment options before specific vaccines and treatments are developed. In early stage Covid-19 patients who do not need mechanical ventilation, CP treatment may be a curative treatment option.en_US
dc.identifier.doi10.1016/j.transci.2020.102867
dc.identifier.issn1473-0502
dc.identifier.issn1878-1683
dc.identifier.issue5en_US
dc.identifier.pmid32620409en_US
dc.identifier.scopus2-s2.0-85087211984en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.urihttps://doi.org/10.1016/j.transci.2020.102867
dc.identifier.urihttps://hdl.handle.net/11616/99381
dc.identifier.volume59en_US
dc.identifier.wosWOS:000594183900027en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherPergamon-Elsevier Science Ltden_US
dc.relation.ispartofTransfusion and Apheresis Scienceen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectConvalescent plasmaen_US
dc.subjectSars-Cov-2 infectionen_US
dc.subjectCovid-19en_US
dc.subjectCoronavirusen_US
dc.subjectImmun plasmaen_US
dc.titleLife-saving effect of convalescent plasma treatment in covid-19 disease: Clinical trial from eastern Anatoliaen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu